DNAnexus, Intelliseq Collaborate for Automated Genomic Variant Interpretation in Precision Health Data Cloud

11 January 2024 | Thursday | News

Integrated and Intuitive workflows designed to generate actionable insights into somatic cancers and hereditary diseases
Image Source | Public Domain

Image Source | Public Domain

-DNAnexus, Inc., the provider of the Precision Health Data Cloud, and Intelliseq, a genome informatics company and innovative provider of next-generation sequencing (NGS) analysis solutions, today announced a partnership to simplify and accelerate variant interpretation and clinical reporting. As part of the agreement, DNAnexus is adding Intelliseq’s automated genome interpretation and reporting capabilities to its Precision Health Data Cloud. The integrated, one-click solution will streamline NGS data analysis and provide scientists with the ability to generate critical insights into somatic cancers, hereditary diseases, and other precision medicine and biomedical research applications.

The combined offering provides users with a complete analysis solution from NGS variant calling to final clinical interpretation, all on the secure and scalable DNAnexus Precision Health Data Cloud. Intelliseq’s iFlow™ Engine translates raw DNA sequences into complete reports with clinical insights. It fits all NGS analysis approaches from a single gene to whole genome. Users are able to take advantage of prebuilt workflows for somatic cancer and hereditary diseases using Intelliseq’s GeneSpect Reporters, or use Intelliseq’s Customica package for custom projects. The two companies will add Intelliseq’s GeneSpect Pharmacogenomics and Polygenic Risk Score Reporters in early 2024.

“DNAnexus has built the world’s most secure cloud platform and global network for scientific collaboration and accelerated discovery,” said Klaudia Szklarczyk-Smolana, CEO of Intelliseq. “The combination of our technologies will help unlock precision health datasets and enable researchers to transform how complex diseases are diagnosed, treated, and ultimately, prevented.”

Today, DNAnexus has more than 40,000 registered users across 48 countries. The company actively manages and supports more than 80 petabytes of complex clinical genomic, proteomic, and other multi-omic datasets on behalf of a growing network of collaborations with leading pharmaceutical, clinical diagnostic, academic research, biobank, and government organizations. The comprehensive cloud platform meets the most rigorous industry standards for data quality, security, privacy, and regulatory compliance.

“This partnership with Intelliseq is another example of how we are committed to continuously improving the user experience for our platform,” said Thomas Laur, CEO at DNAnexus. “Our customers can now take advantage of Intelliseq’s proven, best-in-class tertiary analysis tools on our Precision Health Data Cloud with just the click of a button.”

 

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close